EUVIMEDEUVIMED entdecken
Open Access

Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide

Geno Guerra iD, George Wendt, Lucie McCoy iD, Helen M Hansen, Linda Kachuri iD, Annette M Molinaro, Terri Rice, Victoria Guan, Lianne Capistrano, Allison Hsieh, Veruna Kalsi, Jaimie Sallee und 8 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Geno Guerra und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Antineoplastic Agents, Alkylating, DNA Repair. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCRR NIH HHS, loglio Collective.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temozolomide (TMZ) treatment has demonstrated a variable impact on glioma prognosis. This study examines associations of survival with DNA repair gene germline polymorphisms among glioma patients who did and did not have TMZ treatment. Identifying genetic markers which sensitize tumor cells to TMZ could personalize therapy and improve outcomes.

Methods

We evaluated TMZ-related survival associations of pathogenic germline SNPs and genetically predicted transcript levels within 34 DNA repair genes among 1504 glioma patients from the University of California San Francisco Adult Glioma Study (UCSF AGS) and Mayo Clinic, whose diagnoses spanned pre- and post-TMZ eras within the major known glioma prognostic molecular subtypes.

Results

Among those who received TMZ, 5 SNPs were associated with overall survival, but not in those who did not receive TMZ. Only rs2308321-G, in MGMT, was associated with decreased survival (hazard ratio = 1.21, P = .019) for all glioma subtypes. Rs73191162-T (near UNG), rs13076508-C (near PARP3), rs7840433-A (near NEIL2), and rs3130618-A (near MSH5) were only associated with survival and TMZ treatment for certain subtypes, suggesting subtype-specific germline chemosensitization. Genetically predicted elevated expression of PNKP, compared to normal brain expression, was associated with markedly poor survival in TMZ-treated patients with isocitrate dehydrogenase (IDH)-mutant and 1p/19q non-codeleted gliomas (P = .015), with a median difference of over 70 months in overall survival times. Similarly, NEIL2 and TDG expressions were associated with altered TMZ-related survival only among certain subtypes.

Conclusions

Functional germline alterations within DNA repair genes were associated with TMZ sensitivity, measured by overall survival among adults with glioma. These variants should be evaluated in prospective analyses and functional studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsAntineoplastic Agents, AlkylatingDNA RepairPolymorphism, Single NucleotideGerm-Line MutationDNA DamageHumansTemozolomideMaleFemaleMiddle AgedAdultPrognosisSurvival RateAgedFollow-Up StudiesBiomarkers, TumorYoung AdultDNA Repair Enzymes

Stichwörter der Autor:innen

DNA damage repairgliomapharmacogenomicssurvivaltemozolomide

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingBiomarkers, TumorDNA Repair Enzymes

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • School of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
  • Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

ORCID-Profile: Geno Guerra, Lucie McCoy, Linda Kachuri, Jennie W Taylor, Robert B Jenkins, Stephen S Francis

Förderung

  • NCI NIH HHS
  • NCRR NIH HHS
  • loglio Collective
  • National Brain Tumor Society
  • Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries
  • National Cancer Institute's Surveillance, Epidemiology and End Results Program
  • NCATS NIH HHS
  • Mayo Clinic

Zitieren

APA

Guerra, G., Wendt, G., McCoy, L., Hansen, H. M., Kachuri, L., Molinaro, A. M., Rice, T., Guan, V., Capistrano, L., Hsieh, A., Kalsi, V., Sallee, J., Taylor, J. W., Clarke, J. L., Almaraz, E. R., Wiencke, J. K., Eckel-Passow, J. E., Jenkins, R. B., Wrensch, M., & Francis, S. S. (2025). Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae275

Vancouver

Guerra G, Wendt G, McCoy L, Hansen HM, Kachuri L, Molinaro AM, et al. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae275

BibTeX
@article{Guerra2025,
  author = {Guerra, Geno and Wendt, George and McCoy, Lucie and Hansen, Helen M and Kachuri, Linda and Molinaro, Annette M and Rice, Terri and Guan, Victoria and Capistrano, Lianne and Hsieh, Allison and Kalsi, Veruna and Sallee, Jaimie and Taylor, Jennie W and Clarke, Jennifer L and Almaraz, Eduardo Rodriguez and Wiencke, John K and Eckel-Passow, Jeanette E and Jenkins, Robert B and Wrensch, Margaret and Francis, Stephen S},
  title = {Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae275}
}
Kostenlos starten →